View in EDS HTML Full Text PDF Full Text

Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.

Saved in:
Bibliographic Details
Title: Atezolizumab and paclitaxel as first line therapy in advanced triple-negative breast cancer patients included in the French early access program.
Authors: de Moura, Alexandre1,2 (AUTHOR) alexandre.demoura@curie.fr, Vuagnat, Perrine1,2 (AUTHOR), Renouf, Benjamin1 (AUTHOR), Pierga, Jean-Yves1,3 (AUTHOR), Loirat, Delphine1 (AUTHOR), Vaflard, Pauline1 (AUTHOR), Lafayolle de la Bruyère, Charline4 (AUTHOR), Chaumard-Billotey, Natacha5 (AUTHOR), Hajjaji, Nawale6,7 (AUTHOR), Ladoire, Sylvain8 (AUTHOR), Dabakuyo, Sandrine8 (AUTHOR), Patsouris, Anne9 (AUTHOR), Frenel, Jean Sébastien9 (AUTHOR), Nicolai, Vincent10 (AUTHOR), Alexandre, Marie11 (AUTHOR), Dohollou, Nadine12 (AUTHOR), Grenier, Julien13 (AUTHOR), Bourien, Heloïse14 (AUTHOR), Bidard, François-Clément1,2 (AUTHOR)
Source: Scientific Reports. 11/20/2023, Vol. 13 Issue 1, p1-7. 7p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20452322
DOI:10.1038/s41598-023-40569-9